Truist Securities Downgrades Evolent Health to Hold
Truist Securities set a $7 price target for Evolent Health, lowering its rating to hold, a 29.15% upside from the current price.
Key Points
- Truist Securities downgraded Evolent Health to a hold rating with a $7 price target on June 30, 2026.
- Truist Securities's $7 price target implies 29.15% upside from Evolent Health, Inc.'s ($EVH) current $5.42 share price.
- Shares of NYSE:EVH traded near $5.77 on Tuesday, with a market cap of about $619.8 million and a forward P/E of 14.3.
- Several insiders, including Peter Grua and Craig Barbarosh, bought 41,096 shares each on June 4, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Truist Securities has downgraded Evolent Health, Inc. (NYSE:EVH) to a hold rating, setting a price target of $7. This change was announced on June 30, 2026, as the firm's analyst Jailendra Singh adjusted expectations for the healthcare company.
Truist Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Evolent Health
BlackRock, Inc. grew its holdings in Evolent Health by 557,321 shares, ending with 10,888,872 shares valued at approximately $24.8 million. Cadian Capital Management, LP slightly trimmed its stake by 270,982 shares, now holding 10,814,473 shares worth about $24.7 million. Morgan Stanley also reduced its position by 197,044 shares, resulting in 9,081,079 shares valued at $20.7 million. UBS Group AG significantly increased its investment, adding 2,040,743 shares for a total of 8,150,361 shares valued at roughly $18.6 million. Absolute Investment Advisers, LLC boosted its stake by 1,000,000 shares, holding 7,500,000 shares worth about $3.8 million.
Evolent Health, Inc. Stock Up 17.8%
Shares of Evolent Health traded near $5.77 on Tuesday. The company, with a market capitalization of approximately $619.8 million, has a forward P/E ratio of 14.3 and a beta of 0.833. Over the past 52 weeks, the stock has ranged from a low of $2.10 to a high of $12.07. The 50-day moving average is $4.04, and the 200-day moving average is $4.54. Evolent Health maintains a current ratio of 1.32 and a quick ratio of 1.20, with a debt-to-equity ratio of 248.60.
$EVH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Evolent Health reported revenue of approximately $1.89 billion, reflecting a growth of 2.6%. Despite this, the company posted a negative net margin of 26.3% and a return on equity of -65.1%. Earnings per share were not meaningful due to the company's unprofitability. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Evolent Health, Inc.
On June 4, 2026, several insiders, including Peter Grua, Craig Barbarosh, and Russell Monroe Glass, each purchased 41,096 shares. These transactions were not conducted under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On June 30, 2026, Truist Securities downgraded Evolent Health to a hold rating, setting a price target of $7. Previously, the firm maintained a buy rating with the same target on June 12, 2026. The consensus among analysts is a mean target price of $5.88, with 13 analysts providing opinions.
About Evolent Health
Evolent Health, Inc. offers specialty care management services in oncology, cardiology, and musculoskeletal markets across the United States. It provides an integrated value-based care platform for health plan administration and management. Headquartered in Arlington, Virginia, the company is led by CEO Mr. Seth Barrie Blackley and employs approximately 4,200 people.
Bottom Line
Truist Securities' downgrade of Evolent Health to hold reflects a more cautious outlook, setting a $7 price target. Investors track these ratings for insights into market sentiment, though it's important to remember that analyst opinions are just one factor to consider. Evolent Health's financial performance and strategic developments will continue to be key areas of interest.
Get Evolent Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $EVH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.